Plain-English translation of NCT06741982 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether combining two types of cancer-fighting drugs— and —along with an oncolytic herpes simplex virus can shrink head and neck tumors before surgery. The idea is that these three treatments working together might help doctors remove the cancer more completely and reduce the chance it comes back after surgery.
Even after surgery, many people with advanced head and neck cancer experience recurrence or spread of the disease. This trial explores whether giving the medication and special virus treatment before surgery might make tumors smaller and easier to remove, potentially improving long-term survival and quality of life.
You likely qualify if…
You likely don't qualify if…
You would receive injections on days 1 and 22, take as a daily pill from days 1 to 42, and receive injections of the oncolytic virus directly into affected lymph nodes (two injections spaced 2 weeks apart, with the dose based on lymph node size). After completing these treatments, you would undergo standard surgical removal of the cancer. The trial lasts approximately 6 weeks before surgery, and you will attend multiple clinic visits for monitoring and assessments.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
West China Hospital
Enrollment target
~21 participants
Started
December 2024
Primary completion
December 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xingchen Peng
West China Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.